Intraoperative Hypotension during Liver Transplant Surgery is Associated with Postoperative Acute Kidney: A Retrospective Cohort Study

Alexandre JOOSTEN (joosten-alexandre@hotmail.com)
Hopital Bicetre  https://orcid.org/0000-0002-5214-4589

Valerio Lucidi
Erasme Hospital: Hopital Erasme

Brigitte Ickx
Erasme Hospital: Hopital Erasme

Luc Van Obbergh
Erasme Hospital: Hopital Erasme

Desislava Germanova
Erasme Hospital: Hopital Erasme

Antoine Bema
Erasme Hospital: Hopital Erasme

Brenton Alexander
University of California San Diego Medical Center Library: University of California San Diego School of Medicine

Olivier Desebbe
Sauvegarde Clinic: Clinique de la Sauvegarde

Francois-martin Carrier
University of Montreal: Universite de Montreal

Daniel Cherqui
Université Paris-Saclay: Universite Paris-Saclay

Rene Adam
Université Paris-Saclay: Universite Paris-Saclay

Jacques Duranteau
Universite Paris-Saclay

Bernd Saugel
Central Medical Library Hamburg: Universitatsklinikum Hamburg-Eppendorf

Jean-Louis Vincent
Erasme Hospital: Hopital Erasme

Joseph Rinehart
University of California Irvine
Abstract

**BACKGROUND:** Acute kidney injury (AKI) occurs frequently after liver transplant surgery and is associated with significant morbidity and mortality. While the impact of intraoperative hypotension (IOH) on postoperative AKI has been well demonstrated in patients undergoing a wide variety of non-cardiac surgeries, it remains poorly studied in liver transplant surgery. We tested the hypothesis that IOH is associated with AKI following liver transplant surgery.

**METHODS:** This historical cohort study included all consecutive patients who underwent liver transplant surgery between 2014 and 2019 except those with a preoperative creatinine > 1.5 mg/dl and/or who had combined transplantation surgery. IOH was defined as any mean arterial pressure (MAP) < 65 mmHg and was classified according to the percentage of case time during which the MAP was < 65 mmHg into three groups, based on the interquartile range of the study cohort: “short” (Quartile 1, < 8.6% of case time), “intermediate” (Quartiles 2-3, 8.6-39.5%) and “long” (Quartile 4, > 39.5%) duration. AKI stages were classified according to a “modified” “Kidney Disease: Improving Global Outcomes” (KDIGO) criteria. Logistic regression modelling was conducted to assess the association between IOH and postoperative AKI. The model was run both as a univariate and with multiple perioperative covariates to test for robustness to confounders.

**RESULTS:** Of the 205 patients who met our inclusion criteria, 117 (57.1%) developed AKI. Fifty-two (25%), 102 (50%) and 51 (25%) patients had short, intermediate and long duration of IOH respectively. In multivariate analysis, IOH was independently associated with an increased risk of AKI (adjusted odds ratio [OR] 1.05; 95%CI 1.02-1.09; P < 0.001). Compared to “short duration” of IOH, “intermediate duration” was associated with a 10-fold increased risk of developing AKI (OR 9.7; 95%CI 4.1-22.7; P < 0.001). “Long duration” was associated with an even greater risk of AKI compared to “short duration” (OR 34.6; 95%CI 11.5-108.6; P < 0.001).

**CONCLUSION:** Intraoperative hypotension is independently associated with the development of AKI after liver transplant surgery. The longer the MAP stays < 65 mmHg, the higher the risk the patient will develop AKI in the immediate postoperative period, and the greater the likely severity.

**Trial Registration:** Not Applicable

Background

Acute kidney injury (AKI) is a common postoperative complication following liver transplantation and is associated with increased morbidity, mortality and development of chronic kidney disease.[1–5] One of the most common diagnostic criteria used to classify AKI is the “Kidney Disease: Improving Global Outcomes” (KDIGO) system, which is based on changes in serum creatinine and urine output.[6] However, as urine output is rarely documented accurately in the perioperative setting, increases in serum creatinine are frequently used independently to define postoperative AKI (“modified” KDIGO classification).
Multiple studies have identified patient and donor risk factors for AKI following liver transplant surgery including among others, female sex, obesity, diabetes, high model for end-stage liver disease (MELD) score, large amounts of blood loss, use of hydroxyethyl starch solution, perioperative blood glucose variability, cold and warm ischaemia times, donor age and graft sizes.[7–12] Haemodynamic variable such as intraoperative hypotension (IOH), most often defined as a mean arterial pressure (MAP) ≤ 65 mmHg, has been shown to be one of the most important factors associated with postoperative AKI. [13] Numerous large retrospective studies have shown that IOH is associated with postoperative AKI after various types of non-cardiac surgery, [14–19] but data on such an association in liver transplantation remain scarce.[20]

We therefore conducted a historical cohort analysis to evaluate the association between IOH and the development of postoperative AKI in patients undergoing liver transplant surgery.

**Methods**

This single centre historical cohort study was approved by our Institutional Review Board on December 14, 2018 under the reference P2018/555 with a waiver of informed consent because of the observational and retrospective nature of the study.

We identified all liver transplant patients from 2014 (when the anaesthetic data for our patients started to be computerised) to 2019 with our dedicated operating room softwares (TrackPro® and UltraGenda®, Belgium). We then retrospectively analysed the patients’ electronic medical records, which include a continuous intraoperative recording of vital signs (Innovian® Perioperative Care, Dräger, Lübeck, Germany). All patients who underwent a liver transplant between January 1, 2014 and December 30, 2019 were included except those. With a preoperative serum creatinine value > 1.5 mg/dL, and any patient who underwent a combined transplantation procedure (liver-kidney, liver-heart or liver-lung).

**Anaesthetic protocol**

Intraoperative anaesthesia was standardised according to institutional guidelines. Patients arrived in the operating room and were placed under an infrared heating lamp. Several non-invasive monitors were then applied: a 5-lead electrocardiogram (ECG), non-invasive blood pressure, rectal temperature probe, and a frontal electroencephalogram using bispectral index (BIS) monitoring (Aspect Medical System Inc, Natick, MA, USA). A bladder catheter was inserted. Vascular access consisted of one or two large bore peripheral venous catheters, right femoral artery and vein catheters, and right jugular vein catheter. The left femoral and internal jugular veins were not cannulated in case veno-venous bypass was required. A Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA, USA) was inserted and use of haemodynamic agents was guided using continuous cardiac index, mixed venous oxygen saturation, central venous pressure, and arterial pressure. Rapid infusers, perfusion heaters, and a cell saver were ready for use prior to induction. In case of active haemorrhage, anaesthetists typically guided blood product administration using ROTEM monitoring. General anaesthesia was induced with propofol or etomidate. Antinociception was achieved...
with a remifentanil infusion and anaesthesia was maintained with sevoflurane or desflurane depending on physician preference. Rapid sequence intubation was performed if patients had not fasted appropriately or if they had abdominal ascites. Neuromuscular blockade was achieved in all patients and controlled with a train-of-four monitor (TOF scan, Idmed, France). The choice of muscular relaxant was left to the discretion of the anaesthetist. Fluid administration consisted of a baseline infusion of balanced crystalloid infusion (Plasmalyte®, Baxter, Belgium) and compensation for blood loss with either Plasmalyte®, 3% modified gelatin, or 4% albumin (depending on patient conditions and physician preference).

**Surgical procedure**

Almost all the liver transplantation were performed by recipient hepatectomy without venous-venous bypass, using the vena cava–sparing technique and piggy-back reconstruction. Liver reperfusion was performed through the portal vein first followed by subsequent arterial reperfusion. Biliary reconstruction was carried out with an end-to-end choledochocholedochostomy without a T-tube.

Our immunosuppressive regimen comprised primarily tacrolimus with mycophenolate mofetil and prednisone. Tacrolimus trough levels were maintained at 5–10 ng/mL. Steroids were discontinued approximately 3 months after liver transplant surgery.

**Measurements and study outcomes**

MAP was recorded automatically during surgery at 30 second intervals by our anaesthesia information management system (Innovian). We extracted the raw values: all values < 30 and > 150 mmHg were considered to be artifacts and deleted. For each patient, we calculated the mean MAP value during the procedure and the percentage of case time during which the patient was hypotensive, defined as a MAP < 65 mmHg. IOH was then categorised into 3 levels based on the interquartile range (IQR) values of the study cohort for the percentage of case time during which patients were hypotensive, according to the methodology of Thacker et al [18]: “short duration” of IOH (in the lower 25th percentile), “intermediate duration” (between the 25th and the 75th percentile) and “long duration” (within the upper 75th percentile).

The primary outcome was the development of stage 1–3 AKI, defined using serum creatinine-based KDIGO definitions without taking into account diuresis (“modified” KDIGO classifications) because urine output is rarely documented accurately in the perioperative setting. The three modified KDIGO stages are: 1) Mild injury: creatinine increase of at least 0.3 mg/dl within the first 48-hours or 1.5 to 1.9 times the baseline level during the first postoperative week; 2) Moderate injury: creatinine increase of 2.0 to 3.0 times the baseline; and 3) Severe injury: creatinine increase of greater than 3.0 times the baseline, creatinine level of at least 4 mg/dl, or dependency on renal replacement therapy.

**Statistical analysis**

The normality of continuous data was assessed using a Kolmogorov-Smirnov test. Normally distributed variables were compared using a student’s t-test and are expressed as mean ± standard deviation (SD).
and those not normally distributed were compared using a Mann-Whitney U-test and are expressed as median [25% – 75%] percentiles. Discrete data were expressed as a number and percentage and compared using a Chi square or a Fisher's exact test when indicated.

We used logistic regression modelling to evaluate the association between IOH and the development of postoperative AKI. Univariate logistic models were used to test for association with AKI using the following independent variables: sex, age, ASA class, weight, body mass index (BMI), Child-Pugh score, baseline serum creatinine and haemoglobin, MELD laboratory score, duration of anaesthesia, duration of surgery, fluid volumes (crystalloid, colloid, packed red blood cells, cell saver), estimated blood loss, diuresis, total fluid output, net fluid balance, use of vasopressors, mean case time with central venous pressure > 8 mmHg, preoperative use of different medications (Table 1), patient comorbidities (Table 1), donor age, donor BMI, postoperative fluid balance, use of cardiopulmonary bypass, presence of portal ischaemia or arterial ischaemia and any episodes of MAP < 65 mmHg. Variables significantly associated in univariate testing were then included in a multivariate logistic regression to evaluate their association with AKI. Risks of developing AKI based on the model are presented as odds ratios (ORs) and their 95% confidence intervals. Statistical significance was determined at the 0.05 level. All analyses were conducted with Minitab (Paris, France) and R (www.r-project.org).
Table 1  
Baseline characteristics

| Variables                        | No AKI (N = 88) | AKI (N = 117) | p-value* |
|----------------------------------|-----------------|---------------|----------|
| Age (years)                      | 57 [48–64]      | 57 [51–62]    | 0.85     |
| Male (%)                         | 61 (69)         | 83 (71)       | 0.76     |
| Weight (kg)                      | 75 [61–83]      | 83 [70–94]    | 0.019    |
| ASA score (II/III/IV/V)          | 4/55/28/1       | 1/56/57/3     | 0.99     |
| Comorbid conditions              |                 |               |          |
| ¬ Myocardial injury (%)          | 5 (6)           | 5 (4)         | 0.61     |
| ¬ Arterial hypertension (%)      | 52 (59)         | 73 (62)       | 0.88     |
| ¬ Heart failure (%)              | 1 (1)           | 1 (1)         | 0.71     |
| ¬ Hyperlipidaemia (%)            | 8 (9)           | 28 (24)       | 0.055    |
| ¬ Diabetes mellitus (%)          | 26 (30)         | 32 (27)       | 0.16     |
| ¬ Atrial fibrillation (%)        | 8 (9)           | 11 (9)        | 0.75     |
| ¬ COPD (%)                       | 5 (6)           | 4 (3)         | 0.61     |
| ¬ Peripheral arteritis (%)       | 4 (5)           | 5 (4)         | 0.76     |
| Medication                       |                 |               |          |
| ¬ β blocker (%)                  | 42 (47)         | 50 (43)       | 0.77     |
| ¬ ACEI (%)                       | 6 (7)           | 8 (7)         | 0.87     |
| ¬ ARB (%)                        | 2 (2)           | 1 (1)         | 0.99     |
| ¬ Diuretics (%)                  | 34 (39)         | 64 (55)       | 0.039    |
| ¬ Statin (%)                     | 9 (9)           | 13 (11)       | 0.75     |
| Child-Pugh score                 | 7 [5–11]        | 11 [7–13]     | 0.022    |
| MELD score                       | 12 [9–20]       | 19 [14–29]    | 0.014    |
| Fulminant hepatitis (%)          | 4 (5)           | 8 (7)         | 0.81     |

* Univariate analysis

Data are listed as “value (%)” and or median [25–75 percentiles]. AKI: acute kidney injury; ASA: American Society of Anesthesiology physical status; COPD: Chronic obstructive pulmonary disease; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blockers; MELD: model for end-stage liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus
| Variables                        | No AKI (N = 88) | AKI (N = 117) | p-value* |
|---------------------------------|-----------------|---------------|----------|
| Haemoglobin (g/dL)              | 12.1 [9.5–13.6] | 10.4 [8.9–12.7] | 0.014    |
| Creatinine (mg/dL)              | 0.90 [0.70–1.19] | 1.00 [0.70–1.32] | 0.061    |
| HBV (%)                         | 14 (16)         | 14 (12)       | 0.86     |
| HCV (%)                         | 17 (20)         | 23 (20)       | 0.23     |
| Donor age (y)                   | 56 [46–66]      | 57 [45–68]    | 0.38     |
| Donor BMI (kg/m²)               | 25 [23–28]      | 26 [24–28]    | 0.14     |

* Univariate analysis

Data are listed as “value (%)” and or median [25–75 percentiles]. AKI: acute kidney injury; ASA: American Society of Anesthesiology physical status; COPD: Chronic obstructive pulmonary disease; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blockers; MELD: model for end-stage liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus

**Results**

Among the 242 patients who underwent a liver transplantation between January 1st 2014 and December 30th 2019, 205 patients met our inclusion criteria (Fig. 1).

One hundred and seventeen patients (57%) experienced some type of postoperative AKI (stages 1–3). AKI stage 1 occurred in 53 patients (25.9%) and stage 2–3 in 64 patients (31.1%). Among the whole study cohort, the median [25th – 75th quartiles] percentage of case time that patients had IOH was 21.4% [8.6–39.5]. Consequently, “short” duration of IOH was defined less than 8.6% of the intraoperative case time with a MAP < 65 mmHg (quartile 1), “intermediate” duration as 8.6–39.5% of case time with a MAP < 65 mmHg (quartiles 2–3) and “long” duration as >39.5% of case time with a MAP < 65 mmHg (quartile 4). There were 52 (25%), 102 (50%) and 51 (25%) patients respectively each of these subgroups. Only two patients had no IOH using our definition (0% of case time spent with a MAP < 65 mmHg). Perioperative characteristics of the patients are shown in Tables 1 and 2.
Table 2
Perioperative variables

| Variables                              | No AKI (N = 88) | AKI (N = 117) | p-value* |
|----------------------------------------|-----------------|---------------|----------|
| Mean MAP (mmHg)                        | 78 ± 7          | 72 ± 6        | <0.001   |
| Duration of IOH**                      | 44 (50)         | 8 (7)         | <0.001   |
| • Quartile 1 (< 8.6%) (%)              | 37 (42)         | 65 (55)       |          |
| • Quartiles 2–3 (8.6–39.5%) (%)       | 7 (8)           | 44 (38)       |          |
| Anaesthesia duration (min)             | 460 [411–536]   | 500 [453–583] | 0.39     |
| Surgical duration (min)                | 333 [294–385]   | 376 [324–438] | 0.076    |
| Venous bypass (%)                      | 3 (3)           | 5 (4)         | 0.53     |
| Portal ischaemia (min)                 | 378 [319–458]   | 420 [360–495] | 0.047    |
| Arterial ischaemia (min)               | 28 [24–35]      | 33 [26–43]    | 0.25     |
| Crystalloids (mL)                      | 2500 [1500–4150]| 2100 [1500–3774]| 0.25     |
| Colloids (mL)                          | 650 [0–1075]    | 900 [300–1500]| 0.30     |
| Packed red blood cells (mL)            | 271 [0–1034]    | 753 [241–1339]| 0.013    |
| Cell saver (mL)                        | 211 [0–710]     | 479 [0–956]   | 0.064    |
| Total IN (mL)                          | 6157 [4041–9726]| 8068 [5285–11517]| 0.015    |
| Estimated blood loss (mL)              | 2000 [1025–3000]| 2700 [1500–5000]| 0.006    |
| Diuresis (mL)                          | 368 [203–733]   | 259 [158–425] | 0.26     |
| Total OUT (mL)                         | 2338 [1650–3304]| 3050 [1793–5285]| 0.011    |
| Intraoperative net fluid balance (mL)  | 3660 [2028–5825]| 4684 [2551–7764]| 0.087    |
| Fluid balance at POD#1 (mL)            | 1204 [188–2813] | 2899 [1587–4534]| 0.002    |
| Combined fluid balance (mL)¤          | 4926 [3103–8674]| 8369 [4944–11308]| 0.003    |
| Calculated blood loss (mL) at POD#2    | 777 [535–1450]  | 1222 [698–2080]| 0.010    |
| Mean central venous pressure > 8 mmHg$ | 50 (58)         | 75 (64)       | 0.336    |
| Use of vasopressors                    | 85 (97)         | 117 (100)     | 0.044    |

* univariate analysis

** percentage of surgical time spent with a MAP < 65 mmHg (see text for details)
| Variables | No AKI (N = 88) | AKI (N = 117) | p-value* |
|-----------|----------------|--------------|----------|
| IOH: intraoperative hypotension |               |              |          |
| POD#1: postoperative day 1 |               |              |          |
| POD#2: postoperative day 2 |               |              |          |
| □ combined fluid balance is the combination of intraoperative fluid balance and fluid balance on POD#1 |               |              |          |
| $ mean central venous pressure is the average of all values over the surgery. |               |              |          |
| “Total IN” is the sum of crystalloid, colloid, packed red blood cells and cell saver administration and “total OUT” is the sum of estimated blood loss and urine output. Net fluid balance is the difference total IN – total OUT. |               |              |          |

Data are expressed as mean ± standard deviation, median and [25th -75th ] percentiles or number and percentage (%)

In univariate testing (Tables 1 and 2), patients who developed postoperative AKI had higher BMI (p = 0.041), were more likely to have received preoperative diuretics (p = 0.039), had higher Child-Pugh (p = 0.0022) and MELD (p = 0.014) scores, had lower preoperative haemoglobin levels (p = 0.014), were more likely to have had prolonged IOH (p < 0.001), portal ischaemia (p = 0.047), or packed red blood cell transfusion (p = 0.013), and had higher total fluid input (p = 0.015), estimated blood loss (p = 0.006), and total fluid output (p = 0.011) than patients who did not develop AKI.

In multivariable analysis using the perioperative variables shown in Tables 1 and 2, only BMI and IOH (OR = 1.05 [1.02–1.09], p < 0.001), were significantly associated with an increased risk of AKI. For every one percent increase in case time spent with a MAP of ≤ 65 mmHg, the risk of AKI increased by about 5%.

Compared to “short duration” IOH, “intermediate duration” IOH was associated with a 10-fold increased risk of developing AKI (OR of 9.7; 95% CI 4.1–22.7; P < 0.0001). “Long duration” IOH was associated with an even greater risk of postoperative AKI (OR 34.6; 95% CI 11.5–108.6; P < 0.0001). Figure 2 shows the three different durations of IOH and their associations with the development of postoperative AKI. This suggests that the observed association between IOH and AKI was a dose-response relationship.

**Discussion**

The presence of IOH was associated with an increased risk of developing postoperative AKI after liver transplantation and this association was independent of potential perioperative confounders. Moreover, the longer a patient spent with a MAP < 65 mmHg during the liver transplantation procedure, the greater the risk he or she had of developing AKI in the immediate postoperative period. These findings confirm that IOH is of real clinical importance and should not be overlooked during the intraoperative period.
Multiple large retrospective studies have shown an association between IOH and postoperative AKI,[13–20, 22] and others have reported an association between the duration of IOH and cardiac, renal and neurological adverse events.[13, 17, 23, 24] However, this association remains poorly defined in the context of liver transplantation.[20] To our knowledge, only one study has assessed the relationship between IOH and the risk of AKI in this patient population.[20] In that study, the authors demonstrated that severe IOH, defined as a MAP < 50 mmHg was strongly related to the development of moderate and severe AKI (stage 2–3). Patients undergoing liver transplant surgery frequently experience IOH as a result of various factors, including, among others, the duration of surgery, the severity of bleeding, the severity of the ischaemic reperfusion syndrome and the severity of the end-stage liver disease, characterised by a hyperdynamic state (high cardiac output and low systemic vascular resistance). However, most studies, that have assessed predisposing factors for AKI after liver transplant surgery, focused mainly on preoperative factors, which are often not modifiable. Perioperative risk factors, such as IOH, are, in contrast, potentially modifiable, and may be minimised by close a collaboration between the surgeon and the anaesthetist. Our results suggest that avoiding or at least minimising the duration of IOH may be a valuable target to reduce the development of postoperative AKI.

Importantly, our hospital has no any strict MAP targets for liver transplant surgery (except to avoid a MAP < 65 mmHg) and MAP management is left to the discretion of the anaesthetist in charge of the patient. Two large randomised controlled trials have demonstrated that targeting a higher arterial pressure during surgery (well above 65 mmHg) was associated with a lower incidence of postoperative AKI.[25, 26] In the first, there was a lower incidence of organ dysfunction in the group of patients managed using a targeted systolic arterial pressure closer to the patient's baseline value compared to the control group in which the same blood pressure target was used for all patients.[25] In the second study, targeting a MAP level between 80–95 mmHg in chronically hypertensive patients reduced the occurrence of postoperative AKI compared to two other MAP targets (65–79 and 96–110 mmHg).[26] French national guidelines recommend maintaining of MAP > 70 mmHg in patients with chronic hypertension (which is the case in 60% of our study cohort) in order to prevent AKI.[27] It naturally follows that targeting a strict MAP goal of 65 mmHg can potentially be flawed as a strict definition of IOH is quite challenging. While some authors use a reduction from baseline value” (e.g. a 20–30% reduction from the patient’s preoperative MAP value), others continue to use the well-known "absolute" threshold value of 65 mmHg to define IOH. We decided in this study to choose the latter as this is the most common practice at our institution. The validity of this threshold can of course be challenged, but Salmasi and colleagues demonstrated that management based on an absolute MAP threshold of 65 mmHg in all patients was equivalent to management targeting relative reductions in MAP from preoperative values in terms of incidence of myocardial and kidney injury.[13] Additionally, although the results of a large randomised controlled study supported the individualization of arterial pressure targets in order to reduce the incidence of organ dysfunction (including a reduction in AKI),[25, 28] it is important to remember that such an approach can be extremely challenging to apply in patients undergoing liver transplant surgery, as higher values may potentially increase bleeding, making surgical conditions more challenging. As always, the risk-benefit
ratio should be carefully assessed and future investigation into an optimal definition of IOH is urgently required for liver transplant recipients.

This study has several additional limitations that should be taken into consideration when interpreting our findings. Firstly, it was observational, retrospective, single-centre and included a relatively small sample size. Therefore, a causal relationship cannot be established and our results may not be generalisable to other hospitals with different perioperative haemodynamic and anaesthetic management. Secondly, our findings may be biased by unmeasured confounding parameters at both the patient and hospital levels. Thirdly, as urine output was not taken into account for the classification of AKI, this may have led to a slight “underestimation” of the incidence of postoperative AKI in our study cohort. Fourthly, per KDIGO definitions, we defined AKI as the change in creatinine value between the preoperative value and the highest value during the first postoperative week. This might introduce time-varying confounding or mediating factors, which limit interpretation of the study finding. Fifthly, postoperative hypotension was not taken into account as MAP was less frequently measured in the intensive care unit or on the floor than in the operating room. Sixthly, although all patients had a pulmonary catheter, data on mixed venous oxygen saturation (SvO₂) and cardiac index were not linked to our electronic medical records and thus, could not be assessed in the present study. However, it is important to note that a recent manuscript demonstrated that decreased SvO₂ was associated with postoperative AKI after liver transplantation.[29] Seventhly, we had no data on the occurrence of post-reperfusion syndrome and its importance on IOH duration. Finally, it is important to note that we reported the odds ratio for a frequent outcome (AKI), and the odds ratio can overestimate the risk in this situation.

Conclusions

Our findings indicate that IOH is independently associated with the development of AKI after liver transplant surgery. The longer the MAP stays < 65 mmHg, the higher the risk the patient will develop AKI in the immediate postoperative period, and the greater the likely severity. Avoidance of IOH during liver transplant surgery may thus help reduce the incidence of this severe postoperative complication. Prospective studies are needed to assess whether targeting a higher MAP during this complex surgical procedure can reduce the risk of postoperative AKI.

Declarations

- **Ethics approval:** Not Applicable
- **Consent for publication:** Not Applicable
- **Availability of data and materials:** By request to the corresponding author
- **Competing interests:**
  - AJ is a consultant for Edwards Lifesciences (Irvine, California, USA), Aguettant Laboratoire (Lyon, France) and Fresenius Kabi (Bad Homburg, Germany)
• BS has received honoraria for consulting, honoraria for giving lectures, and refunds of travel expenses from Edwards Lifesciences Inc. (Irvine, CA, USA). BS has received honoraria for consulting, institutional restricted research grants, honoraria for giving lectures, and refunds of travel expenses from Pulsion Medical Systems SE (Feldkirchen, Germany). BS has received institutional restricted research grants, honoraria for giving lectures, and refunds of travel expenses from CNSystems Medizintechnik GmbH (Graz, Austria). BS has received institutional restricted research grants from Retia Medical LLC. (Valhalla, NY, USA). BS has received honoraria for giving lectures from Philips Medizin Systeme Böblingen GmbH (Böblingen, Germany). BS has received honoraria for consulting, institutional restricted research grants, and refunds of travel expenses from Tensys Medical Inc. (San Diego, CA, USA).

• OD is consultant for Medtronic (Trévoux, FRANCE) and received honoraria for giving lectures for Medtronic (Trévoux, FRANCE) and Livanova (Châtillon, France).

• The other authors have no conflicts of interest related to this article

• **Funding:** The authors received no funding for this work

• **Authors’ contributions:** All authors read and approved the final manuscript.

• J: Designed the study, collected and analyzed the data and drafted the manuscript.

• L: Collected and analyzed the data and edited the final manuscript.

• I: Analyzed the data and edited the manuscript.

• VO: Analyzed the data and edited the final manuscript.

• G: Collected and analyzed the data and edited the final manuscript.

• B: Collected the data and edited the final manuscript.

• A: Analyzed the data and edited the final manuscript.

• D: Collected & analyzed the data and edited the final manuscript.

• FM: Analyzed the data and edited the final manuscript.

• C: Analyzed the data and edited the final manuscript.

• A: Analyzed the data and edited the final manuscript.

• D: Analyzed the data and edited the final manuscript.

• S: Analyzed the data and edited the final manuscript.

• V: Analyzed the data and edited the final manuscript

• R: Statistical analysis of the data and edited the final manuscript.

• VdL: Statistical analysis of the data and edited the final manuscript.

• **Acknowledgements:** All the clinicians who helped in data collection from the current liver transplant database.

References
1. Wilkinson A, Pham PT. Kidney dysfunction in the recipients of liver transplants. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2005(11 Suppl 2):S47-51.

2. Cholongitas E, Senzolo M, Patch D, Shaw S, O’Beirne J, Burroughs AK. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol. 2009;21(7):744–50.

3. Velidedeoglu E, Bloom RD, Crawford MD, Desai NM, Campos L, Abt PL, Markmann JW, Mange KC, Olthoff KM, Shaked A, et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation. 2004;77(4):553–6.

4. Hilmi IA, Damian D, Al-Khafaji A, Planinsic R, Boucek C, Sakai T, Chang CC, Kellum JA. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth. 2015;114(6):919–26.

5. Barri YM, Sanchez EQ, Jennings LW, Melton LB, Hays S, Levy MF, Klintmalm GB. Acute kidney injury following liver transplantation: definition and outcome. Liver transplantation: official publication of the American Association for the Study of Liver Diseases the International Liver Transplantation Society. 2009;15(5):475–83.

6. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care (London England). 2013;17(1):204.

7. Iwata H, Mizuno S, Ishikawa E, Tanemura A, Murata Y, Kuriyama N, Azumi Y, Kishiwada M, Usui M, Sakurai H, et al: Negative prognostic impact of renal replacement therapy in adult living-donor liver transplant recipients: preoperative recipient condition and donor factors. Transplantation proceedings 2014, 46(3):716–720.

8. Hand WR, Whiteley JR, Epperson TI, Tam L, Crego H, Wolf B, Chavin KD, Taber DJ. Hydroxyethyl starch and acute kidney injury in orthotopic liver transplantation: a single-center retrospective review. Anesthesia analgesia. 2015;120(3):619–26.

9. Yoo S, Lee HJ, Lee H, Ryu HG. Association Between Perioperative Hyperglycemia or Glucose Variability and Postoperative Acute Kidney Injury After Liver Transplantation: A Retrospective Observational Study. Anesthesia analgesia. 2017;124(1):35–41.

10. Cheng Y, Wei GQ, Cai QC, Jiang Y, Wu AP. Prognostic Value of Model for End-Stage Liver Disease Incorporating with Serum Sodium Score for Development of Acute Kidney Injury after Liver Transplantation. Chin Med J. 2018;131(11):1314–20.

11. Cabezuelo JB, Ramírez P, Ríos A, Acosta F, Torres D, Sansano T, Pons JA, Bru M, Montoya M, Bueno FS, et al. Risk factors of acute renal failure after liver transplantation. Kidney international. 2006;69(6):1073–80.

12. Thongprayoon C, Kaewput W, Thamcharoen N, Bathini T, Watthanasuntorn K, Lertjitbanjong P, Sharma K, Salim SA, Ungprasert P, Wijarnpreecha K, et al: Incidence and Impact of Acute Kidney Injury after Liver Transplantation: A Meta-Analysis. Journal of clinical medicine 2019, 8(3).
13. Salmasi V, Maheshwari K, Yang D, Mascha EJ, Singh A, Sessler DI, Kurz A. Relationship between Intraoperative Hypotension, Defined by Either Reduction from Baseline or Absolute Thresholds, and Acute Kidney and Myocardial Injury after Noncardiac Surgery: A Retrospective Cohort Analysis. Anesthesiology. 2017;126(1):47–65.

14. Hallqvist L, Granath F, Huldt E, Bell M. Intraoperative hypotension is associated with acute kidney injury in noncardiac surgery: An observational study. Eur J Anaesthesiol. 2018;35(4):273–9.

15. Sun LY, Wijeysundera DN, Tait GA, Beattie WS. Association of intraoperative hypotension with acute kidney injury after elective noncardiac surgery. Anesthesiology. 2015;123(3):515–23.

16. Jang WY, Jung JK, Lee DK, Han SB. Intraoperative hypotension is a risk factor for postoperative acute kidney injury after femoral neck fracture surgery: a retrospective study. BMC Musculoskelet Disord. 2019;20(1):131.

17. Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013;119(3):507–15.

18. Tang Y, Zhu C, Liu J, Wang A, Duan K, Li B, Yuan H, Zhang H, Yao M, Ouyang W. Association of Intraoperative Hypotension with Acute Kidney Injury after Noncardiac Surgery in Patients Younger than 60 Years Old. Kidney blood pressure research. 2019;44(2):211–21.

19. An R, Pang QY, Liu HL: Association of intra-operative hypotension with acute kidney injury, myocardial injury and mortality in non-cardiac surgery: A meta-analysis. International journal of clinical practice 2019, 73(10):e13394.

20. Mizota T, Hamada M, Matsukawa S, Seo H, Tanaka T, Segawa H. Relationship Between Intraoperative Hypotension and Acute Kidney Injury After Living Donor Liver Transplantation: A Retrospective Analysis. J Cardiothorac Vasc Anesth. 2017;31(2):582–9.

21. Thacker JK, Mountford WK, Ernst FR, Krukas MR, Mythen MM. Perioperative Fluid Utilization Variability and Association With Outcomes: Considerations for Enhanced Recovery Efforts in Sample US Surgical Populations. Annals of surgery. 2016;263(3):502–10.

22. Mathis MR, Naik BI, Freundlich RE, Shanks AM, Heung M, Kim M, Burns ML, Colquhoun DA, Rangrass G, Janda A, et al. Preoperative Risk and the Association between Hypotension and Postoperative Acute Kidney Injury. Anesthesiology. 2020;132(3):461–75.

23. Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. Br J Anaesth. 2018;121(4):706–21.

24. Maheshwari K, Turan A, Mao G, Yang D, Niazi AK, Agarwal D, Sessler DI, Kurz A. The association of hypotension during non-cardiac surgery, before and after skin incision, with postoperative acute kidney injury: a retrospective cohort analysis. Anaesthesia. 2018;73(10):1223–8.

25. Futier E, Lefrant JY, Guinot PG, Godet T, Cuvillon P, Bertran S, Leone M, Pastene B, Piriou V, et al. Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery: A Randomized Clinical Trial. JAMA: the journal of the American Medical Association. 2017;318(14):1346–57.
26. Wu X, Jiang Z, Ying J, Han Y, Chen Z. Optimal blood pressure decreases acute kidney injury after gastrointestinal surgery in elderly hypertensive patients: A randomized study: Optimal blood pressure reduces acute kidney injury. J Clin Anesth. 2017;43:77–83.

27. Ichai C, Vinsonneau C, Souweine B, Armando F, Canet E, Clec’h C, Constantin JM, Darmon M, Duranteau J, Gaillot T, et al: Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies). Anaesthesia, critical care & pain medicine 2016, 35(2):151–165.

28. Godet T, Grobost R, Futier E. Personalization of arterial pressure in the perioperative period. Curr Opin Crit Care. 2018;24(6):554–9.

29. Kim WH, Oh HW, Yang SM, Yu JH, Lee HC, Jung CW, Suh KS, Lee KH. Intraoperative Hemodynamic Parameters and Acute Kidney Injury After Living Donor Liver Transplantation. Transplantation. 2019;103(9):1877–86.